-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 HBbcx4BVTMXKxw9tPAKOjHRlM2LC8Sr/dFlxWhVmTyWJwMBkJ7q7TD6/1G+37yZG
 YW6OyVVhP9EX9VZqEwBikA==

<SEC-DOCUMENT>0001144204-08-065108.txt : 20081118
<SEC-HEADER>0001144204-08-065108.hdr.sgml : 20081118
<ACCEPTANCE-DATETIME>20081118105651
ACCESSION NUMBER:		0001144204-08-065108
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20081118
FILED AS OF DATE:		20081118
DATE AS OF CHANGE:		20081118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		081197277

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v132741_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      the
      month of November 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Valley
      Cottage, New York 10989</u></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F&#160;<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x
</font>&#160;&#160;Form 40-F&#160;<font face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): <font face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): <font face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;&#160;&#160;
      <font face="Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
<font face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
      by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated November 18,
      2008 is hereby incorporated by reference into the registration statements on
      Form F-3 (File No. 333-141529, File No. 333-147024 and File No. 333-153055)
      filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
      on March 23, 2007 , October 30, 2007 and August 15, 2008, respectively, and
      the
      registration statements on Form S-8 (File No. 333-148058, File No. 333-148574
      and File No. </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>333-154795</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>)
      filed by XTL Biopharmaceuticals Ltd. with the Securities and Exchange Commission
      on December 14, 2007, January 18, 2008, and October 28, 2008,
      respectively.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="logo.jpg"></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Announces Top-line results from the Bicifadine Phase 2b
      Study
      for Diabetic Neuropathic Pain</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Study
      failed to meet its primary endpoint</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York, November 18, 2008 </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
      XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) announced today the top-line
      results from the Bicifadine Phase 2b clinical trial for the treatment of
      diabetic neuropathic pain. The trial&#8217;s primary objective was to compare the
      efficacy of two doses of Bicifadine against placebo in reducing pain associated
      with diabetic neuropathy. The primary endpoint of the study was the reduction
      in
      pain score during the course of treatment. The company announced that the study
      failed to meet its primary endpoint. The trial also failed to meet key secondary
      analysis.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, CEO of the company, commented: &#8220;We are all very disappointed with the
      results of the study. We will devote the next few days to further analyze the
      data and decide on the appropriate course of action for the Bicifadine program,
      and for the company.&#8221; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div align="left">
      <table border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td align="left" colspan="2" valign="top" width="48%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
                BIOPHARMACEUTICALS LTD.</strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
          </tr>
          <tr>
            <td align="left" valign="top" width="50%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                November 18, 2008</font></div>
            </td>
            <td align="left" valign="top" width="3%" style="border-bottom: #ffffff solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font></div>
            </td>
            <td align="left" valign="top" width="45%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/
                Ron Bentsur</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Ron
                Bentsur</font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            <td align="left" valign="top" width="45%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Chief
                Executive Officer</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/P"C`P$1``(1`0,1`?_$`,\````%!0$!````````
M```````("0H+`0(#!0<$!@$``0,%`0````````````````('"`$#!`8)!1``
M``8!`@0#`P0*$`8#`````0(#!`4&!P`1(1(("3%!$R(4"E%A%19QD<$R0F(C
M,Q@Y\(&AL5)RLS0U=;;6%S=WM]'A5)5X&9=(6!$``0($!`(&!08*"`8#````
M`0(#`!$$!2$2!@<Q05%A<2(3"(&1L3(4H<'A<K(5T4)28B-S)!8V-_#QDM(S
M0X-4@J+"4W07-$1%_]H`#`,!``(1`Q$`/P!_@4_XWC\O*'[^K4I>\X"/1"`L
MG!+:IQIK'8H:J0,Y:;"_3C(&MPTG/S<DMS&081$.R7D9)ZMZ93&%-JS;'4-L
M`CL'AI3*'ZBH31TN4K<(`,\<Q,L!ZH'GD4].I^H[K:02>P0RTN_Q:-B89O>)
MT#I4KM@Z=XZ=78M9.:N<Q'97L]=;.C-QLK-%NT6JT&\?-TP7;L%2.2@0X%4<
M%,(\LE;?Y>*JLLJ%.5P%Y*<P1+N2XF?.8[<>4,G5;PL(KRPRB="F8/3,'#'A
M#P/`.;*-U&83QIG?&L@O(T/*U1B;K6G#A/T7A8Z80]<6CY'<P-WT<X]1NN0!
M'D62,&X[;ZCK=[=56N[5%IJ5CQ:=12?093GT&4/!:JYN\6YFN:P0\F8CKXJ`
M7@.XCQVXAOP^;8/^&L%"U)`2<@/;],9JIJ,\F$5`_P"-]L?N[!N&JI\.7Z7*
M%3Y'Z85/-C)0/4/HBO/^,'V]*_9^D>N"7U_5]$#G_&#[>C]GZ1ZX)?7]7T0.
M?\8/MZ/V?I'K@E]?U?1`!0!$2[[B&VX>7'P'?A^P=4SLI5E3QZIF#)S43EZ\
M#&4OCY>'[//5T\)PD>'.2>,7#Q`0^8=4[.,*QY<8\@B4A4R&YC!OPV`=MO#R
MW\/WM60]X2R7U`*5PPPA/B.M#@I:CQ($>A+[P.(FXFV$=A';F'Y-7$3RXJ"N
ML0(EE[I)'7\L5,4!Y1'\$=_W!#27!,`]!BI`)!/(QYQ/RF,'-RD*&X\-]@\1
M'?<>)0XCI+CCBP/#!XXF`-OJ<SD@(.`$5`2J[;'X;?)[0^(?;X?)I:7VDK\/
M.E2SUCYH4IM/!Q)*NO#\$9R;<H;;[?C>/B/CJX1(Q267"4HOU2"!H@@:((2)
M[R,SURXYZ3YG.70CDMS4+YA9=Y<,@4U&FUBY&OF,BMMK&:,:6"*E%T)RH)I%
MD4P;\OKMB+D$!-R:W3;VGTW5ZB:M^ITG[N?.5!2<I"N68F8D3U#E&J:R7>:6
MTKK;0LAY`F>SI'9_3G#.C`GQ!/6K-97JM:ZP<N-\H]+U\-(8]S=5V%"HU=?*
MXYR#&N:I-6**EX2#CY)I+59G*C()`FJ)%!;F(8IRF#4GM0;,V"BMBKAI]I0N
M]/)QDA4TKD0H3PQ!E(R(PG#'V/7=YJ+D*.[N^);7%97"KBGIEPE*>$P8^]L7
MPQ?7*[RHTA\-VS"EWZ>[`\0DZ/GEY>B1J:>/IHR#ROS$K22,7,XZF&\*Y(<R
M3$R[=RH`"FL!!W#$MN_6G*2T`7)IQ.H&4*0MI(.0.#!(X'"8D9J](C.?VEKG
MKFNJI%)59GE`@D@JRDS49S&(!PP[08\W5+WB.H?HLNU4Z)>WEFAK`].W2'1(
M?!9;D[IM,M#G+N1*ZJZ6R-D(%Y^/F3L(YU;W3INR3;J`B"2(F'F$V^K&G-K+
M9J6G<U3K-M35PNBRMM"#E2V#[H(()X2Q)@U%K2MTY4MV&S+;^!I$@)..91''
M,09$=0"90LGT@]4_=&E^T_UE=P?J,STN,Q_@[:IKI6@5L;4"&&&;5;F%QEF4
M09UQL633GI/=M&MW'.V.T;G6$@@JF;35:ITYHT;AT&C-.I"LZT^,M2LR>(FD
M$2E(&9Z^?$1O=HN^H?W-J[W<U*^\&DDH2.!PPF)$\9<Y2G#=,OQ$/=D+P'JB
MC#>`[ABC%(^)0';?ZKCYZD$G8W0:?>2%(3@2%\QQAIAN7K!0S)<RX\"/PB,I
M?B&N[:<O.3J<CC)[[<P8DQ68-_DY@JVVJ+V7V\6)T].Z1.4\\_8(MG='5:>X
M7AXHQE(</5%!^(<[M)3<I^J&*(;;?8^)<5!P\O&L!JG_`*2V_!R.("7.M<"=
MTM6$9LY*>H#\$6E^(=[M8CRAU011S?P28FQ4(_:"L&'5UC8O0*U!I8275<`E
M?TQ56Z.K99PLA'6D?@A3/L^]Y#N)=5?<.P+@W.6=6MNQC=/KR-DKR..Z!!'D
M0A:+8)J.+])0U?9R#<$)%@F?\FH7F`-AW`=:'N?M7I/2VD:J[VIM8K65(`FJ
M:>\0#RG\L;3HK6E]ONH6:&X+FTY.<N@`D#HY=$/MTQ$1X_P0X>7E^WJ(Z3FR
MK/%29^R)#``(`'3&8>("&KG#&*0WKQCUI]2L_P!UF=Z;I7(OO>&FN4,C5YO5
M0KE=143AJ]59.4BF@2Z4:65-Z#MH01.*HG,'`1U,S4&SVBJ+R[-;@M-.?O&J
MA8=*BH%.=QYM"L)<,JSSXRQCGGI;?'<"Y^;!_;9RK!TH*ZH:R9>]D::<6G'A
M/,@3,N!,I0X*04$2<0'AOMN`\>(_A#PU"\I2P<N9`:Y`\1/TQT-5)+I:`5AS
MEACCQBY0PB)2@(!S#P#8?D$>([[<-4Q<,P4ED8F1QA.3,J1,DC$X?/!"^X]D
MG,^)NE^T7;`RLNCDEC8*>VBSP5<+:WX,'TVDWEQ)!F82?O)`9"(F-Z0\A>.X
M:='9RSZ<U#KJGM.K'4-:;6TLE96ELYTB:05J[H23@<.$\88_S#7?6EAVQJ;Q
MH5#CFI45#2&T(2I9R+7E4H)3B5`8IY3E,$81H>V9EC/&8NG`]PZAUYM>_ER!
M;(H#3M63J#TL`R^CS1!?HDD=%\Q!*N?E6]+\H'GPUZ&^6GM&:6UW]V:,4V]:
M/AD+"D+2]WR"5`+1A(=$8/ELU%KK4FWIN.Y(>1?!4*1)U!;.02`,B`9],*)E
M4_)[AL`!X;\?/SV'<--`LN%(*0<QZ01_5#^`I`[I2&N1G,&`*IN8```V$`_!
M'?[/CX#H6%E(RD)43S$_G$72DY04XCMC(`FX<2^/R"`_O^.E("@G])(JZL!\
M\!ET&<7ZK"8\+QDB];.&CENW=-G;=9HZ;.DR+-W+9RF9%=!PB<HD6052,)3D
M$-C%'8=6QG0L.H$G)CG[LN8BJPAUM33F*%`@CMB,C[Y_;?7Z`.K:1?TJ(50Z
M=<]K2UYQ(L1,YX^L2)E@7N.,5%O:32-6GSGUF)!$.:+<)`&_IGVGCM%KM>I-
M,M4SI2Y>:-7A*0>*F@D%*^N<U#T1%3</3+NG[BIQ@2M]1W@0<0J>((PE*#;X
M&[[UQQ%VA;UTH#+RJO5'6G),,X1MI4UEEV&#;7'O575J6DN58"36-8\KB(9`
M8P&$SED<O!(PZT^^;0M5FXZ+LP$"Q/)+[@F`?%1CDR\<JU2)]/3'K46XCM)I
M`VY"U_>;4FT=TRRJXG-PF!P'1"<G:6[>=B[BO5K6<9NT'Z.&*0=I?,_6UN98
MQ6M(8O`,A66[X-S%L]]D"@Q0VW."0N'!@]C?3@;HZT:T'I(U1"'+E4)R--\<
MF$I@#'`8^B->T+I@ZNN_CU)4:=LYG">/'E/C/Y(E!%\1XW=8V)AYY1JN_P`5
M$J[6E?X=2,.Q?U`]18L48UI75H1TDLR<1*3!NFEZ)RF(($`1`1U`GXRJ0^*U
ME9%<%9@N?>GQXQ*Y-,PBF-&$`TZA(CJE*4%Z'MY=!Y1#FZ,NF/Q';;"F/!`.
M([>,`'`?DU["=7:J`,Z]X!6$IGCVSYQXKFF;`5A:J-H@<_HB/^^(=QAC7#_<
MLN=%Q10Z?C6H,L18?D$*I1:W$U:O(R,G"R*\B^1BH5HR9$</%"E%0_)S&$O'
M4Q]A:ZHK])BX7-];V9Y:1FQ/=,N/81$=]TZ6BH-2?#T30:1X(X<R9&'!_P`-
M_P!)G3!FKMT'N.7^G?"V3K:7/F5(LMFOF-JA:IX8QB2N&8Q_TM,Q;M][HS]4
M023$_(F!AY0XZ9;>Z_WVV:W71T%0XVR&@9`R&)./;PAQ]M++::_3`>JV$..*
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MF+L4@F`.4O,<XB!2@(CKI-?Z>JN?E&HZ6A:=<J7Z.F80E*227`^VK`#\623)
M7`F0YQR*TY<;9I[SIU]UN3R&*"FN%4XXM9"0E)9<3+'\;,H#+QXP;3)G?GAV
MMB>QN%<&/+C6&#I1#ZSV^Q.8!223(;F3<-(:%C)5:,0<(^V3WI8#\@@8Q2[B
M4&CLGD]O-5;V:O45ZHK=='D!7@%'BR!$TC.'$!2B)%0RC*>Z>$/MJ3ST6^BN
M3]#I?3U;=;6RXI/Q(7X6:1[QR>&O*E)F`2HY@`<)P:'I#[P&%.H^V0V.[K7W
M^'+[8509UPLG*-INGVB6$"F&)B9])LS78R"A=^1%XBF"ABB4AQ,)2CH^Y_E=
MUWMY9QJ8.LW#3@.52FDE+B3(F9;S+)2`"2>`AP-I?-[H?<N]?NU64R[1>\H4
M`XX%H6<P&3-E1E/`B<YP>7JQZCXCI6PI8LW3=;E[5&UM_!,5X.(<-&$DZ/.R
M[6(2.FXD-FI$T3.`,(&XCY:97;?1E9N7J:BTG;E^!75(>RE?=`2VE:EE4Y2(
M2E1`GB9`<8?;=?<BCVIT37:RK*=54S2NLA2$]#JT(!29'FH8RPQ/*-7T=]4L
M)U>8;0S+7JE+TV,=6*P5H(6<?,Y!^FXKSE))=XJY8%*U]%?UBB0`W$OGKT]S
MMNJK:_5SFF+@^*BX(I6UYD"0*5B8`F58RX]<6=H]R[=NQHIK5=NIU4U,X^M&
M5??(4@XSD$X=<%TZR.Z+@SI)E'5)%O(Y0RJW1*X>TRIN6C5K7/6Y`0+;9]XH
MJQB7*Q#<Y6I2*N?3]LQ"`(".X;8;`Z[W-I7+_1_LFF$*"2\\,N)XY$F7B"?$
MI("3@8;7>/S.:#VA=197LMRU8N9-.R9!$C@'",_AJ(E))$SQA.EGWZ;NTD"/
M+3TM`UIZRA/0?1USE&LDJ@8VX^YN9FMDAG;STQW*3F`AA#@.GL1Y-V7CX-%J
MRD<NR\`TIJ0G*?O>-(=$Y0P%/Y\G\S;URTI4HMRU8J#A[J?RO\.1PXRETPLS
MTH=:F$>L"L+S6+IA\E.0QVY;32;$V(PM-;.N`BBHZ:IJ*-WT<X$H^D[:G4;G
M'@(E-[(1KW#VJUCM5=3;=5M]Q?\`AN(.9M8G^*L8$@2*AQ`,3"VLWDT7O!:5
M7#2E1D>94$N,N22X#+&229J1RS@2G!P-P^4--Y.'5S)Z1%=5BL)+=[/`6!L]
M=O+/:.>;%$4.-QG5GF4*/DB1;E<N:7D&M-UAKJC)N39V^"S.7`1"K1$>=T1[
MR%*)^3;>=M;Q=[/K*F59255+R@VI'(I)Q/HXSZHT_7%!1UNG7UU(FMI!6D]!
M']/GB+3`Y@*F90NQN0.?AML(I[!N)0`P%#@'#P#;Y-="WO@@A*%__,*1/J61
M@/7$.@M2UJ`/=G,>@Q),?#CT#IOJO;?HMGP9)(S]QO\`.2\EU!S;ULW;6-#+
M<<J+-Y4I1!,QUF\54HL4$HM,3"DJT5]X+L*QM0%W:JKY4:Q>I;P5!3)DVGEE
MX@CMB5^W5+0T^G&WJ4#QGO>/7_3U^B%_=-K#C1A5\2?9TE7+ZPBVY[A[1\\1
MM?Q,?ZUR_?Z+X1_L_(ZFQY?_`.7R/_)=^T(C!N]_%G^DCV"'+_PN7ZL8_P#Y
M%Y>_DZQIDM^_YA.?J$^TPZFU'\*-_KC[!'=?B+?U2W4-_7>(/]U*GKP=GOYC
M47UC]E4>KN3_``C5>CVPS-^'V_6U=+GV,G?[8VW4K]\?Y>7#]:W]H0PVV'\6
M4O8KV*B3P3_.#_%^[J`+?NH^H(EM_E^F,YMN4=_#8=_L;:N0D<1+C#(;/>,'
MN;.Y_DO$+%PHU/?^I%[7UG27YQM&NGC168<E,'AZ$6DL;<>`"`"/R:ZR:0U*
MC2GE[HM25I2&:"S!32")A2\@D9=ICAWKC3-1K+S/7/2B4J+M=J-2'%)G,(+A
MF.R7LAX7B[`.(<,TF.H>-Z#6*]7(MBBQ])"&CSN9,J1!*9[,OE6YGDM(N1$3
MJK+G.8QS"/`.&N6MXU;J+45U7>+O6O/5CBU+*@XI(0%3*)"9D`F0$I=,=D-/
MZ&TOI2QIT_I^@IVJ-E(3(MA17+WRHGWB3,GE/A#>[O3])E&Q>IC_`*CL5PC*
MEN+5:/J?=HVM-21<<O/>Y+S-;MS5!D"+>-ERG8+IJJ)$(*BGIG'VR[C-_P`G
MFX=PU`JOVWU"/C:537B-K6K.<I6&R@SX^\",9X&.>GG?VJMFE1;MU-*CX2X&
MI#+K3:<@!"%.!T2/&:<I$OQA+HCN74SF.2SOV583(L\X%U8WK?',-9W)B@!W
M=AJN0&M<D7"@@(AZCU:-*N(^?J".M-VWTNC1?FW.F996J=ZK4WU-J:<(`[$F
M7HC?=U]9#7GDK;U,ES+4/)HVW>MQ#K:%#TD",?;\S"K@+M(9+S"W`AY&F6#+
M3J"0/MR+V-_(1</7DQ*;V3E&7D$1$H\#`&WGI6_NE5ZX\S-#I]CA4-TJ5?5R
M$J]24F%>7C6'[A^4FZZI<]ZC<J,OUNXD>G,L06#M`=*D#U)9%R/U*9R8_7UC
M4+*1M#,;4(RS*TY,FN>=G+%.)N_52EOH-%8GHHK`9+U5RFY1Y"@&]>:;7XV_
MM-KVWT<\NDH*JGFI+>$@WW"!+'O*!,^H\X;#R:[;M[EZENFZFM$FK>8J.Z'$
MYDE3@S`S.!DDCLPAS3:<:T*WUEW3;53:U8:P_9G8NZ[+0\:XB%&7HBD1$C0[
M04FY$R`!2&3`HI[`)=A`!U`FCO%XMMR374-?4HN*3G"LYF3.?3TB9G/KCII<
MM-:9NEN5;Z^WTJ[;(I*2VD`!0DHC#H/*4-,\H5J2[77<>@)/'[Z1;XW<R5=L
M+-DLZ,8LAB6[2!HRPT^4$3<[U*`=)KE;*'YAYVZ1]^<#"/2;3]:SYD_+Y5T5
M^4DZJMS3@;4`,ZG6TDH(/YTN'.<<G]0L5OE9\RS#ME"?W9KEH+;8GE^%=4/&
MF)RS(&:1_-AWG]-PW_6D_H?ZP??F_HCQ]]\/S7[NN9_PER_[1_Q/!_X^CZT=
M8OO"U<,__P!?XC_3XYHVZI0`@"&XAP*`%VW'<=N`;#OQ'PUC!:VTC)CF,>OX
M:77?$5R$,$OB3>YN.=,N%Z&\.6)-QB;!\Z#W,<M&./49WG,3-)0C>LF5;G$C
MJ#QH1R)5"_A3!SC]\V(.I;[%;=FBI_WU=[MT>);0")$-"2@H]2BHD=$NN([;
MHZN9J718*4_LR#F41^49@CT##UPDI1NUSGN^=N/)'<4BV+L*51;PTC&%/]P5
M/*6?&D4#B.O64(Y01!4T-4K$N@V`A2"55NFY5W_(AITJK<NS4.M6]'5"TD.L
MK"US$DKE@GM.,:A2Z-N3FFUWUM'Z1*DE(EB4\SV#">//A!G.P_W*5N@_JE9T
MO(DT=KTU=0DC"T_(A7:Y@C:5;!6]QIV4$BF.!&J<8Y="QE3`'Y2.6$X[B@7;
M6MZ-ND:ITZ+E18UE$,R)"94.)`^;KCU-L]1G3UY^!JY"GJS)<\,N.$_7$ETV
M=-W22:S=5-=NL0JJ*Z)BJ)+)*%`R:J2A!$BB2I#`8I@$0,4=PX:@PDNE\L5`
MDL8CKB4K:T.ISMF8BX=O9V#;8XA_SU=SE8$^(7+U1;<65H)/2(C;_B8_UKE^
M_P!%\(_V?D=3:\O_`/+Y'_DN_:$1@W>_BS_21[!#E_X7+]6,?_R+R]_)UC3)
M;]_S"<_4)]IAU-J/X4;_`%Q]@CNOQ%OZI;J&_KO$'^ZE3UX.SW\QJ+ZQ^RJ/
M5W)_A&J]'MAF7\/SL'=KZ5Q$?O@R>'+OY_X9VK81`!W#[7EJ66^:W5;=U;84
MV$!Y!E^-[WS\H87;!1&IZ<>'/'CV@X^CYXD[RCL8!]H?8$`V`1W`1*.X\.`\
M-<_4.!"2A628(ZN7IB6RRK(<P,LW+CSC)S[\``^_SE';]OYM)6Z"A0!3.1Y]
M79%I)&88+XPTBQLY8->^-)GDC$32/U&W\J!U!#E]\<5":;L`*(\!%1V<"E`.
M(F$.&NE.H&:ASR@L):!+J+92YI=$FYGU<8Y#:0?8H_.XIQX@,HOM:D'\YU3T
MOMB4.V2@02E$1W,4.4-_$?$!W^SKFJ_F2Q)'O&7R1UWFRM[Q#[Z5'VPB=WUY
MB.:=)E,B7*Y47TUF>M'CD#;`=8D;!V%R_$I=^8`:H*`)A`.&_P`X;RU\F5&]
M7;N?&J$J5B@4I?8'$8_@B$OGQJT4NTE*PI0-;479!0.<D-.+.'4$B?;!-Y"%
M=PG859>_IG1^F+FRFVGJ<#*1TEF/9FN0!#B1RB@!R^0E-OITZ&JHZSSP.KIC
M-A+SHGRF*)4-!6TM72>0-*:E)#RG4+$_R7;B%@^I4:/%D+(S/8DS$G&>J)V6
M2IR7>D2+S">+B<A51W(<P!OLDFV()S#Y`72]35E/1^<BA76R#/A);!.&+C;F
M4_\`-*,72%#45?D5N[=""I[XDK5+&0:>9=5Z@F#F=B*P0[GIHR36FZI#S<)F
M:0>R38.7U4V<Y7H)2,=F#??TE`8K%`?E((!IKO.=15%-N9;JK*KX$T!2DRPG
MF<G]H>N'8\A%[IW]L+A0)4/CV;GF4.>1Q",9<93"H7($Q"E#@/M'$.4.)A'Q
M'QVV`!#42UMN!:7`<$`D]8EA$[%.)8(0.&8)'IQ^>&H/?&EV%@ZM<7UR*Y'4
MY&XJK;!\V1W.L1U/W.57B6IP(!ORBB1RG*''@J'RZZ,>4,JM^V=YN3X\.A=J
MBHJ5@"AIL%9'9(SCDWYZ7T7/>6S6.D_25#5,E)"<3G=5W!Z<.V')_P!69C?^
M9C_D3]6/$W]-\O\`,_XVWGJ#OWK;^G_]SQ>7^%T]D=(/NY^?N8_NYX7^I+AZ
MH3$[X'<SC.WITK/FE0G&+?J0S@A+4O#,:*Z7OM?1.V%*SY.=-A,*J;"G,G(>
M['$`*I)JH$#<.;;TMK-!OZYOR:8R1:FN\X5&1YR`/7+U1Z6LM1N6*PJ=I1FK
M5X#"<@<)R]D1\/1!TJWSK[ZL,;]/=1D'CV6R#9/I;(%Q54/(KUJC,W))7(-Y
MF79S']=VA'J*F344,)G+U=(O$QQU,'5&H[?H;3[E05H`IVO";0DB9*1AT8GA
M/JB-NGK#5:GO:6'$+!<5G7/B<2203R_JB5KH>!\68TPC6^GBKU*+0Q#6*`TQ
M<SISANDK&.:<G$FA'4=()"0".PE&JJIG9C`(KJ+',.YC:Y]N7.HN%V=O+JUB
MM6]XF:?,&>'5/E$O6+?34MO1;6T_LZ&L@!YB4L>L^V(O7NN="$GV\^L._P"&
ME45O\++&=>^8+FWH'!*8QK/NG`,H<'6P$<R=.?%/%.2!N8/024-[*H"/0+;?
M65+JW2"'*MYE%R92$%,I)F!+O">/3/G.<1,UA8ZBQZ@6CPEJI5*S`@XX]!`P
M^@]$/!_AQ.YFGU48&5Z3,L6=*2SUTZ0C1&OR$@_(M*9"PPD9)A`RP'44.L^E
M:2J)(Q\.XF,@+58=^<PZBSO'HEG3FH?O2B*30O3/=,P%'%78#Q'7.'LVTU8[
M=:/X"J015HGC*4TCYQ#F0"''8!$OLCY!Y>7'?QV#30*"5#N8*XCMASW05K&0
MCPYXCG,1&U?$RK($[KM_(HLDFH&&,("`'.4H\GU?DP$=A'YM33V""&="`5#[
M:&P^N0.!F5$'GTIPB,>[2'#JCQBVM37@@"73),N1ZX<N_"W*%4[8BADSD.'Z
M1V7R@8H@8O`E9\PW#AIE-^ELKW!=6RL+;\!&(AU-JT*&E@C*4J"R1/L'9'=?
MB+C\G:5ZB3*&(0I9O$(<QA`H!ME.IB(B(CL`:\/:+(G<.WK*@A!69D_5,>CN
M*2-(NI6E2UJD"$^DX>J(X7"6>\F].&2ZWF/"5[<8_P`G5,DB6NV^*2B7;^*"
M8CW$7(^[I2S.08F][CW:B1N=(WLFX:G)?+=9M0T+UJNP9>I'',2)!1"3W1/'
MA$6;=<KE9ZU-;;$N-N(X3F<>?1"A/_O6[JF^_P"FQ?O^QXX_N=K1O_56W`$O
MA6?6/P1L*M?:W*U+^(=!49R$Y>@0/_>OW5?+K8OV_P#4>-_NT[;5%[5;=%!"
M:1G,098CCRY15.O];A0/Q#O'K@]_2]<NHOJ`M=&S!6YR3OW4B]8.LV.II(C%
M.PV&Q5),TY+2+5A&MV;5Y)J,V8C[HBD07)0,F4-QU(NH.A-/;2L:?U4Z&+!6
M4J*9:`H9D8!">]+NX@3,O5'/&Z4VM*_?FOO.E&%NWZDN!K`"@D+4DYU8<QB<
M(<TXV[ZN"EJA'M\Q8_R'5LBLV96L^PJL0SG(->;1*<CQ1F+N3BY*)26<E$?0
M=HE51,;D$1Y>;4)[YY2]:.5WBZ.K[94V9]1-.XMQ05D5B,Z`E0PG*>;&4Y#A
M$Y-.>>/0GW4E.M[;<K??6)AY"6PM&=)(.514@C-+,4Y3*<IF$W<VY7S3W>NH
MJE8]Q93).N8RIZQV\>5X<'R%3BY%PW+9;]>99H96*:RJC),I&;0AA,?8$B<X
MF,8)`:1T[I7RM:(K=0ZHK6G]:U+!2I#:@4*[N9+30XS"IDKYC\41';6VL]5>
M;[<:W6+2M$\UHVF>*LZT%.1"AX:UK/">6<N@]D*Y=SC'=;P_VPI;%];(*5;H
M2&'ZU&&5Y"J*-(FT0C,72IB^R"SHY#*G';[XXZC%Y>[S4:D\P])?'E2K*Y;[
MZIG!(4VM.'8@RETR,2N\SNFZ?1_E:J=+6@*-)1"C83/O*4$.MF9E+$J$R>B<
M?.]H6FUC)G;HF<?65`)&LW.YY@K4PW#E.*L?+F;,W'I&,4Q"K()J<Y#"'LJ`
M`Z]?S27EZT;]_O!:9KJ:%%*M)!FG.VD3S#F"1B)QY?E$T]1ZB\N+^F+LA:*2
MO>JFW9X&3J0B:/R9#%/'$0E;4IK.W9QZI)]M8*K)W'#]M5/%*KAO'P.0JDBY
M,[@I:$FU`/'1]XKJ1^51NXY?;,H0=B&*;4AKM;]*^:S1%&];:I--K>B9GD5(
M)2Y.:DK$\Q"B.Z9##$3E$7=/.:Z\G6Y]8W<J1RLT%6?HR\A!/B-3S)6D\$K3
M.1./`PIA<N^YTYL:@M(4J@9,G;DJR4]TK\W&Q$!#-7JB!O0"3L(S#Q-1HF[V
M*H*"?.<H^QI@[/Y.=TJB[HI+N_;V+>'/TCH<*NYP[J2D`D<?>B2]V\]VV#=F
M^(L%+<*B[J)2AIQM*0E8`D2I*UDB<A+*.F".]#73;F'KTZJC]8V?(MVVQU$V
MUM<UUY%B]8LKC8XM9NK4J=3F3Q-,ZE.K`MD3.'`"9%0$03`14,?9WMYM<:2V
M8VZ:VCT0^W5W-QE;3RTD**/&&5Q2B.!,R0.76!#(;%;6:TWMW8>WBW$9736Y
MNK14MH4DI"RTL+;;2#ADP`(YB?"<.LN57YO'?R\?#?P\=M<\Y".J>;J$<PN>
M$L1Y'?L93(F*,:7Z2C6JC%A(W6DUJTOV3%58%SLF3N=BGZ[1H=8.<R:9BD,?
MCMOK+I:^YT$_@:IYJ?Y)4GV*$8;]NM]4/VEM*^T`CY8QT_!F'<>RKB:Q_B+&
M-#EG+$8Y>5I='J]7DW+$ZI5E&*[^$B&+I1FHHF0QDQ.)#&*`B'#15U]RKFLE
M94O.B<Y+4I0^4F+;%MH*5[XFG:0BH`RS``[OJ^2.K%*8.`[;!MMQ'PUA*&:2
MI`*&'KCT%D'AQCG%[P[BO)J\<ZR+C+'F0',,FNE$KWBF5RV*QR3DQ#.D&"D]
M&/SL4G)DRB<$A(!S%`3;[:SJ:OKJ)!31/.M3..52DS[9$1A5%%2UCX75M(<2
MD83`)^4&-;4<"82H$T2QT3#&**184FZ[1&>J6/ZG79E-J[Y0=M22<-$,GI&S
MDI`]0@*<A^4.8!V#2:BXW2O'A7%]UUCD%+4KY%'"$,VVAI%%VC9;0\>8`'L$
M=8*4^_M%*`;CX&$1^81X!QVUBIF$25QGAV<HSBAN4Q/-\\<FMV`\(WZ:4LMZ
MPSBBZ6-9LV9+3ELQ]4K',K-&8'(T;JRTS#/'YT&B9Q!,@GY2`8=@#62+E=Z6
MG\"WU#J$SG(+4E/7@#QC">M]%5JS5C3:SU@'VB/K:A0:9CR'^@,?4VIT:"][
M5??0=1K\56H?WQR)?>GGT="-&3073@"!SGY.8X@&X\-6G7ZJJJC4UCBW%9`)
MJ)4?6<9=$9=,S34K?A,("&^@`#Y,(]=MIM5O<&ZK-UK%<N-=?G0.^@+5#1T_
M".SME2N&YW,5+-7C%P=NX3*<@G3-RG*`AQ#56GGZ=T/4RU(=3P()!]!&(BCK
M3+Z?#?2%-=!QCD7Z*/3&'_UKP`/AQ##^/O(```XUW?@`;:SE7N^DS3750'ZQ
M9_ZH\]5HM>;NTK!'6E,_LF!^BETQ?_FK`'_Q!CW^[ND_?5__`-_5?VU_WH3]
MT6S_`&E-_93_`'8'Z*/3$/`>FK`&P\/\H,>_W<U47N_@S%?53_6+_OP?=%L_
MVE-_93_=C["MX4Q-3'S.2IN+\=U%\P2.W9/:S3*Y!O&3=4O(HFS<QL8W5:D4
M((E,4@E`Q1$/#5:N\7:X4II+A55#[9,Y+6HB?3(J,8M#IG3ULN!NM!;Z5JXD
M%)<2E(60>.(3,^N.:WWHTZ6LH3*UDR!@#%EJL3I=1P[F9.JQOT@[6/Q,L^=-
M4&RCY8VP;F5YQ'6QV?<[<C3E&+;8KS<&+:D22TE]:6T].5&($SB92QQC5[SL
M]M7J"N7<[W8+55W!Q69;CE.V7%'\Y>69D,!.>`CKE$QA1,81)(''=*J5'AB\
MF\94X*.@69O3)RIG52CFR'O"H?PU.8WSZU>YW:\7U]=7?:EVKJ5\2XHJQYF9
M)Y=0C:[/INP:>I?A+!0TU"R!@&4)2#+D<H&$;ZQ5>$ML6O"6>"A;%#NO2,O%
MSL>TF(Q8Z!P52,O'OT5FJPI*E`Q!$HB4W$-8U-4UE!4(J+<ZMBH0)!Q!*5@<
MP")$`CKC-N%MH+O1?!79AJIIE8J:<`4@D<#(@@]/#",-9IU;IT8$-5:]`UF(
M!=5T$778IE"1WO+@X'7<@RCT$&X+K&#<Y^7F.(`(ZNU5;75U0:NN?<>J")9E
MDJ.'#$DF+=%9;1;*04%KIVZ:@!S>&V`E.;L$A&"WT6J7V%<UZZ5>N6Z">!LZ
MA+-$,IJ+<?@@91G((N&XF*7P'DY@\ATF@K;G:ZGXNVU"Z:JG/.W-*ICAB"#A
M"+K8;'J%@4>H*1BJH0"/#<0E:1Z%"6,%ZBNA+H^A)4DU&=-F'6TDFJ+@B_U,
MC%R)KF$!$Q&KI)=H4H"&X`"8`'D`:W1[=+<NII!0U%]N+E,)]TNKEB)&7>P)
M'1&@T6QNSULK/C[=IRU,56:94AA"3QGC(8XXRX<X-,QCFL:U;,6+=NS9-$TT
M6K1HD1NV;()\$T&[=(I4D44R\"E*`%``V#6B+SNU*JMY:UOK&)423ZR8<Y%.
MPTVFGIT);ID`94I``$N4AA*-AHB]%I1,(\0V_:'1!%VB"*#N`<.(Z((`;B''
M@.B"*Z((&B"!H@@:((&B"!H@@:((&B"!H@@:((&B"!H@@:((&B"!H@@:((&B
#"/_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
